You searched for Gout - Page 8 of 96

Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Anna Kretova¹, Carlijn Wagenaar¹, Wendy Walrabenstein², Daisy Vedder², Dirkjan van Schaardenburg² and Martijn Gerritsen¹, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…
Abstract Number: 2015 • ACR Convergence 2024
Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
Austin Barry¹, Harlan Sayles¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Kaleb Michaud¹, Bridget Kramer¹, Jeff Newcomb¹, Mary Brophy³, Anne Davis-Karim⁴, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Veterans Affairs, Boston, MA, ⁴Veterans Affairs, Albuquerque, NM, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is associated with decreased health-related quality of life (HRQoL). The ACR endorses treat-to-target (TtT) urate-lowering therapy (ULT) for gout with a serum urate…
Abstract Number: 2016 • ACR Convergence 2024
Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)
Anusha Moses¹, Martijn Oude Voshaar¹, Tim L.Th. Jansen² and Mart Van De Laar¹, ¹University of Twente, Enschede, The Netherlands, Enschede, Overijssel, Netherlands, ²1VieCuri Medisch Centrum, Venlo, Netherlands
Background/Purpose: Both the European League Against Rheumatism (EULAR) and the American College for Rheumatology (ACR) state that gout can be effectively managed by reducing sUA…
Abstract Number: 2018 • ACR Convergence 2024
Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study
Tillmann Uhlig¹, Lars F Karoliussen¹, Joseph Sexton², Sella A. Provan², Espen A. Haavardsholm³, Nicola Dalbeth⁴ and Hilde B Hammer¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: People with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy…
Abstract Number: 2020 • ACR Convergence 2024
Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Peter Lipsky¹ and anthony yeo², ¹AMPEL BioSolutions, Charlottesville, VA, ²Independent consultant, Ann arbor, MI
Background/Purpose: Pegloticase is a pegylated recombinant uricase approved for treatment of chronic uncontrolled gout. Because of the development of anti-drug antibodies (ADA), persistent urate lowering…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 2022 • ACR Convergence 2024
Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Sharan Rai¹, Gregory Challener¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate levels and are associated with reduced risk of incident gout as well as recurrent flares [Annals IM…
Abstract Number: 2023 • ACR Convergence 2024
A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout
Frank Fan¹, Riyong Liu¹ and Yu Wang², ¹Chongqing PegBio Biopharm Co.,Ltd., Chongqing, China (People's Republic), ²Hangzhou Grand Biologic Pharmaceutical, Inc., Hangzhou, China (People's Republic)
Background/Purpose: For patients with refractory chronic gout, i.e., those who have frequent gout flares and/or persistent tophi despite treatment with the highest tolerable doses of…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 2123 • ACR Convergence 2024
Epidemiology of Bone Health and Fracture in Gout Patients
Emily Holladay¹, Alexis Woods², Lissa Padnick-Silver³, Fenglong xie⁴, Jingyi Zhang⁵, Angelo Gaffo⁵, Jeffrey Curtis⁶ and Brian LaMoreaux², ¹University of Alabama at Birmingham, Edmond, OK, ²Amgen, Thousand Oaks, CA, ³Amgen, Thousand Oaks, ⁴University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶FASTER Medicine, Hoover, AL
Background/Purpose: Gout is an erosive arthropathy, and gout patients have been shown to have a higher occurrence of osteoporosis and fracture. This study evaluated bone…
Abstract Number: 2557 • ACR Convergence 2024
The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study
Zhiqiang Wang¹, Sarah Tilley², Christine Peloquin², Eva Petrow³, Margaret Clancy² and Tuhina Neogi², ¹Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, Guangdong, China (People's Republic), ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston Medical Center, Boston, MA
Background/Purpose: Colchicine, an anti-inflammatory drug commonly used in gout, has been associated with a lower incidence of total knee/hip replacement compared to placebo among participants…
Abstract Number: 2559 • ACR Convergence 2024
Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis
Brooke Kelly¹, Gregory Gamble¹, Anne Horne¹, Anthony Doyle¹, Jill Drake², Opetaia Aati¹, Chang-Nam Son¹, Ramanamma Kalluru³, Kieran Latto¹, Lisa Stamp⁴ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, New Zealand, ³Health New Zealand, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. The aim of…
Abstract Number: 2560 • ACR Convergence 2024
Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study
Hilde B Hammer¹, Lars F Karoliussen¹, Lene Terslev², Espen A. Haavardsholm³ and Tillmann Uhlig¹, ¹Diakonhjemmet hospital, Oslo, Norway, ²Rigshospitalet-Glostrup & COPECARE, Glostrup, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway
Background/Purpose: Ultrasound (US) is sensitive for detecting monosodium urate (MSU) crystal depositions in gout, described as double contour (DC), tophi and aggregates. Depositions decreased during…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Robert Keenan¹, James Cheng-Chung WEI², Sarah Morris³, Pamella Mundell³, Wen Wei³, Ke Shi³, Zancong Shen³, Vijay Hingorani⁴, Shunqi Yan³, Bahram Kiani⁵ and Litain Yeh³, ¹Arthrosi Therapeutics, Inc., Chapel Hill, NC, ²Chung Shan Medical University, Taichung, Taiwan (Republic of China), ³Arthrosi Therapeutics, Inc., San Diego, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…

Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial

Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy

Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)

Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study

Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase

The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies

Could Initiation of Sodium Glucose Co-Transporter-2 Inhibitors Reduce the Need for Conventional Urate-Lowering Therapy and Flare Medications in Patients with Gout?Population-Based Target Trial Emulation Studies

A PEGylated Mammalian Uricase Suitable for Intramuscular Administration to Patients with Refractory Chronic Gout

Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis

Epidemiology of Bone Health and Fracture in Gout Patients

The Relation of Colchicine to Knee/hip Replacement Among People with Gout in a Population-based Cohort Study

Relationship Between Serum Urate and Changes in Dual Energy Computed Tomography MSU Crystal Volume over One Year in People with Gout: An Individual Participant Data Analysis

Continuous Reduction in Ultrasound Detected Crystal Depositions over 5 Years Follow-up: Results from the NOR-Gout Study

Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women

AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography

Simple Search Results